Mr. John Karagiannidis reports

DIAGNAMED ENTERS ACQUISITION AGREEMENT TO ACQUIRE COLCHESTER EAST NATURAL HYDROGEN PROJECT IN NOVA SCOTIA

Diagnamed Holdings Corp. has entered into an acquisition agreement to acquire the Colchester East natural hydrogen project in Nova Scotia, consisting of 30 licences totalling 2,104 claims.

This strategic acquisition positions Diagnamed directly within Canada's most active and rapidly expanding natural hydrogen corridor -- a region that has recently drawn significant attention from major global players, including Koloma, which registered thousands of claims across the Cumberland basin and Rio Tinto, which recently secured a large block of claims immediately to the south. This unprecedented staking surge underscores the geological potential of the basin and places Diagnamed alongside industry leaders such as Quebec Innovative Materials Corp.

The acquisition also complements Diagnamed's existing land position in Ontario's Temiscamingue hydrogen corridor and supports the company's strategy to advance next-generation natural hydrogen extraction technologies.

CEO commentary

John Karagiannidis, chief executive officer of Diagnamed, stated:

"This acquisition represents a strategic opportunity and positions Diagnamed among the largest natural hydrogen claim holders in Canada. With major industry groups like Koloma and Rio Tinto now aggressively securing ground in the area, it's clear that this region is emerging as one of North America's most competitive natural hydrogen frontiers. Our entry into this district is timely, deliberate and aligned with our goal of deploying cutting-edge extraction technologies across multiple high-potential jurisdictions."

Strategic importance of the Colchester East project

The Colchester East project is located directly east of the natural hydrogen properties held by Quebec Innovative, which recently reported significant natural hydrogen concentrations in the region. The project also lies immediately adjacent to the recent major staking initiatives by Koloma to the north and Rio Tinto to the southwest.

The acquired licences exhibit the same key geological indicators observed on neighbouring discoveries, including fault-controlled migration pathways, caprock configurations and proven hydrogen-bearing stratigraphy. Together, these features provide a robust foundation for Diagnamed to execute systematic exploration using its emerging proprietary technologies.

Acquisition terms

Under the terms of the acquisition agreement:

• Diagnamed will make a non-refundable cash payment of $10,000;
• The company will issue 10 million common shares to the sellers;
• Sellers will retain a 2.0-per-cent royalty on hydrogen or mineral revenues;
• Diagnamed may repurchase 50 per cent of the sellers' royalty for $2-million.

The transaction is subject to approval from the Canadian Securities Exchange (CSE). All securities issued will be subject to a statutory four-month-and-one-day hold period. The sellers are arm's-length to the company.

Corporate update

Diagnamed is pleased to announce that Fabrice Consalvo has joined its board of directors. Mr. Consalvo brings more than 30 years of global energy sector experience, including leadership roles with Areva, Accenture and Investissement Quebec. He is currently the founder of Gamanergie Consulting, advising international clients on building efficient and profitable energy ecosystems.

His appointment strengthens Diagnamed's governance, technical focus and commercialization strategy as the company expands its natural hydrogen portfolio.

About Diagnamed Holdings Corp.

Diagnamed is a Canadian technology innovator focused on developing advanced natural hydrogen extraction technologies to support the rapidly growing hydrogen sector. The company is committed to delivering scalable, cost-efficient and sustainable solutions essential to global energy security and decarbonization.

We seek Safe Harbor.